Having trouble accessing articles? Reset your cache.

In pair of trispecific deals, AbbVie expands access to Harpoon tech, gains NK cell engagers

AbbVie’s expanded partnership with Harpoon is the company’s second deal in as many days focused on developing trispecific engager therapies. While the Harpoon deal is focused on T cell therapies, the other, with Dragonfly, could mark the pharma’s entrance into NK cell engagers.

Under the deal with Harpoon Therapeutics Inc. (NASDAQ:HARP),

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers